Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Petta, Vasiliki; Loukides, Stelios; Κostikas, Κonstantinos; Papaioannou, Andriana Ι.; Papatheodorou, Georgios; Cholidou, Kyriaki; Tomos, Ioannis; Papiris, Spyridon; Koulouris, Nikolaos; Bakakos, Petros

doi:10.21037/jtd.2018.01.45

Cited by 10 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies conducted on patients have found increased serum levels of OPN in smokers as compared to non-smokers. 24,[26][27][28] In the present study however, no significant difference in levels of OPN was found between smokers, ex-smokers and non-smokers in patients with ILD as well as COPD. Similar results have been forwarded by a study, where it was found that smoking caused concentration dependent increase in OPN levels in cultured endothelial cells.…”

Section: Discussioncontrasting

confidence: 77%

Diagnostic Role of Osteopontin in Interstitial Lung Disease

Goyal¹,

Jaswal²,

Garg³

et al. 2021

J Health Sci Med Res

View full text Add to dashboard Cite

Objective: Early diagnosis of interstitial lung disease (ILD) is desirable not only to better define pathobiological mechanisms, but also to customize treatment protocols. As osteopontin (OPN) expression may be linked to the fibrotic remodelling in ILD, this present study was planned to evaluate the usefulness of its estimation in serum for the diagnosis of ILD.Material and Methods: Serum OPN levels were estimated by enzyme-linked immunosorbent assay in 52 diagnosed cases of ILD, that were then compared with 46 patients with chronic obstructive lung disease and 46 apparently healthy controls.Results: Median levels of serum OPN were found to be significantly higher in patients with ILD, 2.186 nanograms per milliliter (ng/ml), as compared to patients with chronic obstructive lung disease and healthy controls (1.687 and 1.923 ng/ml, respectively). The best cutoff levels of OPN, for diagnosis of ILD, was found to be >1.08 ng/ml; with a sensitivity of 88.4% and specificity of 32.6%. Of the various subtypes, serum OPN levels were found to be highest in patients with idiopathic pulmonary fibrosis and interstitial pneumonia with autoimmune features; although the difference in levels between various subgroups was not found to be statistically significant (p-value=0.495).Conclusion: Serum concentration of OPN was found to be increased in patients with ILD and may be used to aid diagnosis. This opens new avenues for future research in patients with ILD, not only for the validation of the diagnostic abilities of OPN, but also as a potential target in its treatment.

show abstract

Section: Discussioncontrasting

confidence: 77%

Diagnostic Role of Osteopontin in Interstitial Lung Disease

Goyal¹,

Jaswal²,

Garg³

et al. 2021

J Health Sci Med Res

View full text Add to dashboard Cite

show abstract

“…Some studies describe that advanced stages of NSCLC present higher levels of serum OPN compared to the early stages [111]. However, other studies did not detect a significant difference in OPN concentrations according to TNM classification [154,155]. In those studies, the limited number of patients with early-stage disease may be the cause of a lack of statistical significance, which is more compatible with what is observed in daily clinical practice.…”

Section: Reviewmentioning

confidence: 77%

Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight

Lamort

Giopanou

Psallidas

et al. 2019

Cells

120

View full text Add to dashboard Cite

The glycoprotein osteopontin (OPN) possesses multiple functions in health and disease. To this end, osteopontin has beneficial roles in wound healing, bone homeostasis, and extracellular matrix (ECM) function. On the contrary, osteopontin can be deleterious for the human body during disease. Indeed, osteopontin is a cardinal mediator of tumor-associated inflammation and facilitates metastasis. The purpose of this review is to highlight the importance of osteopontin in malignant processes, focusing on lung and pleural tumors as examples.

show abstract

“…The high AUC value of 0.893 for SPP1 expression level indicated promising utility of SPP1 as a biomarker in the lung for the prediction of LC risk in patients with COPD, although the sample size was not large enough. A previous study using serum OPN to predict cancer risk in patients with COPD identified a rather small AUC value of 0.636 [33]. There are two forms of OPN, intracellular form (iOPN) and a secreted form (sOPN) [34], and sOPN may be produced by many cell types, including hepatocytes, cholangiocytes, hepatic stellate cells, macrophages, T lymphocytes and natural killer T cells [35].…”

Section: Discussionmentioning

confidence: 99%

High expression of SPP1 in patients with chronic obstructive pulmonary disease (COPD) is correlated with increased risk of lung cancer

Miao

Xiao

et al. 2021

FEBS Open Bio

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airway inflammation and fixed airflow obstruction. Patients with COPD have increased risk of lung cancer (LC), and the coexistence of both diseases is associated with poorer survival. However, the mechanisms predisposing patients with COPD to LC development and poor prognosis remain unclear. Gene expression profiles were downloaded from the Gene Expression Omnibus. Twenty-two data sets were included (n = 876). We identified 133 DEGs and 145 DEGs in patients with COPD and LC compared with healthy controls, respectively. There were 1544 DEGs in patients with LC and coexisting COPD compared with COPD, and these DEGs are mainly involved in the cell cycle, DNA replication, p53 signalling and insulin signalling. The biological processes primarily associated with these DEGs are oxidation reduction and apoptosis. SPP1 was the only overlapping DEG that was up-regulated in patients with COPD and/or LC, and this was validated by qPCR in an independent cohort. The area under the curve value for SPP1 was 0.893 (0.822-0.963) for the prediction of LC in patients with COPD. High expression of SPP1 in patients with LC was associated with shorter survival time. Up-regulation of SPP1 may be associated with increased risk of LC in patients with COPD and therefore may have potential as a therapeutic target for LC in patients with COPD.Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) are leading cause of morbidity and mortality worldwide. COPD is characterized by persistent airway inflammation and fixed airflow obstruction [1]. The overall prevalence of spirometry-defined COPD is 8.6% among the general population aged 20 years or older, accounting for 99.9 million people with COPD in China [2]. It is currently the third leading cause of death worldwide and imposes huge economic burden on patients [3]. LC is the number one cause of cancer deaths worldwide with a low 5-year overall survival rate [4,5]. A previous study has

show abstract

Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Abstract: OPN levels ≥35 ng/mL could predict the presence of LC among COPD patients. In patients with LC and/or COPD, LC is the major determinant for serum OPN. Serum OPN might be a promising prognostic biomarker of LC and a diagnostic biomarker of LC among COPD patients.

Cited by 10 publications

References 32 publications

Diagnostic Role of Osteopontin in Interstitial Lung Disease

Diagnostic Role of Osteopontin in Interstitial Lung Disease

Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight

High expression of SPP1 in patients with chronic obstructive pulmonary disease (COPD) is correlated with increased risk of lung cancer

Contact Info

Product

Resources

About